OncologyOnline.net

Oncology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Retevmo"

Selpercatinib ( Retevmo ) is a highly selective and potent small molecule RET kinase inhibitor. Researchers have reported an update on the efficacy and safety of Selpercatinib in RET-fusion+ non-smal ...


RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers ( NSCLCs ). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective RET inhibition are unknown. ...